Pomalidomide is a cancer medicine used in the treatment of multiple myeloma (a cancer of the bone marrow). It is also used in combination with bortezomib (i.e. cancer medicine) and dexamethasone (an anti-inflammatory medicine) in geriatric patients who have received at least one treatment including lenalidomide.
Pomalidomide Market: Introduction
- Pomalidomide is a cancer medicine used in the treatment of multiple myeloma (a cancer of the bone marrow). It is also used in combination with bortezomib (i.e. cancer medicine) and dexamethasone (an anti-inflammatory medicine) in geriatric patients who have received at least one treatment including lenalidomide (another cancer medicine). It is also used in combination with dexamethasone in geriatric patients who have received at least two prior therapies, including both bortezomib, & lenalidomide whose disease has worsened. Pomalidomide is used to treat various types of cancers including multiple myeloma, Kaposi sarcoma etc. It works by slowing or stopping the growth of cancer cells or carcinoma cells.
- Pomalidomide directly stop angiogenesis and myeloma cell growth. This dual effect is central to its activity in myeloma or cancerous cells, rather than other pathways including TNF alpha inhibition, since potent TNF inhibitors involves pentoxifylline & rolipram do not inhibit myeloma cell growth or angiogenesis. Up regulation of IL-2, interferon gamma and IL-10 as well as down regulation of IL-6 have been observed by pomalidomide. These changes may contribute to pomalidomide's anti-myeloma & anti-angiogenic activities.
- The pomalidomide market can be segmented based on type, indication, end-user, and region. Based on type, the market can be categorized into 1mg Tablets, 2mg Tablets & 4mg Tablets. Based on end-user, the market can be split into hospitals, clinics & others. In terms of indication, the market can be categorized into AIDS, Kaposi sarcoma, Cancer, Multiple myeloma, and others.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81947
Key Drivers, Restraints, and Opportunities of Global Pomalidomide Market
- Rise in burden of cancer, multiple sclerosis, and autoimmune disease, together with growing FDA, fuels the global pomalidomide market. Pomalidomide is majorly utilized in the treatment of relapsing and remitting forms of cancer and AIDS. Pomalidomide is a capable candidate for the treatment of HIV AIDS. The role of pomalidomide among the increasing number of treatment options is estimated to further boost demand. It is promising for other diseases such as Kaposi sarcoma & myeloma.
- Pomalidomide could even causes harm to unborn babies when administered during pregnancy, women consuming pomalidomide must not become pregnant. A "Risk Evaluation and Mitigation Strategy" (REMS) program was developed to avoid the embryo-fetal exposure and ensure pregnancy prevention or distribution of the drug to those who are or might become pregnant. Women must produce two negative pregnancy tests and even utilize contraception methods before beginning pomalidomide. Women must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control, beginning four weeks prior to initiating the starting treatment with pomalidomide, during therapy, during dose interruptions and continuing for four weeks following discontinuation of pomalidomide therapy.
Request for Analysis of COVID-19 Impact on Pomalidomide Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81947
North America to Capture Major Share of Global Pomalidomide Market
The higher cases of multiple myeloma in the U.S. is a key factor responsible for the dominance of North America. According to statistics by the American Cancer Society around 32,110 cases of multiple myeloma were diagnosed in the U.S. in 2019, while around 12,960 deaths occurred in the same year. Rise in cases of multiple myeloma is boosting the pomalidomide market in the region. Moreover, the favorable reimbursement structure is also estimated to propel the market. Additionally, the presence of a majority of key drug manufacturers is further fueling the market. However, the market in Asia Pacific is anticipated to expand significantly during the forecast period, due to the rising patient base. Furthermore, increasing rate of adoption of pomalidomide in the region as well as the support from governments along with non-government organizations, is anticipated to boost the pomalidomide market in the region.
Pre book Pomalidomide Market Report at-
https://www.transparencymarketresearch.com/checkout.php?rep_id=81947<ype=S
Key Players Operating in Global Pomalidomide Market
The global pomalidomide market is highly fragmented, with the presence of various key players. A large number of manufacturers hold a major share in their respective regions. Major players operating in the global Pomalidomide market are:
- Celgene
- Natco Pharma
- Intas Pharmaceuticals
- Indiabulls Pharmaceutical
- Cipla
- Glenmark Pharmaceuticals
- Dr Reddy's Laboratories
- Qilu Pharmaceutical
- Chia Tai-Tianqing
- Hanson Pharm
- Meidakang Huakang Pharmaceutical
- Shandong Kongfu Pharmaceutical
- SL PHARM
For More Information- https://www.transparencymarketresearch.com/pomalidomide-market.html
Browse more Market Reports:
Collagen and HA-based Biomaterials Market:
With animal-derived constituents progressively becoming a part of healthcare, especially in the case of collagen sources, religious and cultural beliefs are increasingly hampering the acceptance and adoption of collagen and hyaluronic acid-based biomaterials. Pigs and cows are a rich source of collagen, and the usage of products derived from these sources is problematic in different regional markets, as such, negatively impacting the growth of the global collagen and HA-based biomaterials market.
Neurostimulation Devices Market:
The trend of implantable neurostimulation technologies is driving the growth of the neurostimulation devices market. Companies are exploring untapped opportunities in the development of new lead interfaces in external pulse generators. Innovations in new lead interfaces are overcoming the drawbacks of conventional lead interface designs. Clinical challenges associated with traditional lead interface designs are triggering the demand for new lead interfaces.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453